AAAAAA

   
Results: 1-25 | 26-33
Results: 1-25/33
IMPROVEMENTS IN PELVIC EXENTERATION - FACTORS RESPONSIBLE FOR REDUCING MORBIDITY AND MORTALITY
Authors: GOLDBERG JM PIVER MS HEMPLING RE AIDUK C BLUMENSON L RECIO FO
Citation: Jm. Goldberg et al., IMPROVEMENTS IN PELVIC EXENTERATION - FACTORS RESPONSIBLE FOR REDUCING MORBIDITY AND MORTALITY, Annals of surgical oncology, 5(5), 1998, pp. 399-406
THE CLINICAL-VALUE OF DIGENE HYBRID CAPTURE HPV DNA TESTING IN A REFERRAL-BASED POPULATION WITH ABNORMAL PAP SMEARS
Authors: RECIO FO SRIVASTAVA BIS WONG C HEMPLING RE ELTABBAKH GH PIVER MS
Citation: Fo. Recio et al., THE CLINICAL-VALUE OF DIGENE HYBRID CAPTURE HPV DNA TESTING IN A REFERRAL-BASED POPULATION WITH ABNORMAL PAP SMEARS, European journal of gynaecological oncology, 19(3), 1998, pp. 203-208
PROSPECTIVE SEQUENTIAL TRIALS OF INDUCTION WEEKLY CISPLATIN FOLLOWED BY MONTHLY CISPLATIN, DOXORUBICIN, CYCLOPHOSPHAMIDE AND PACLITAXEL ANDCISPLATIN IN OPTIMAL (LESS-THAN-OR-EQUAL-TO-1 CM) STAGE-III AND STAGE-IV OVARIAN-CANCER
Authors: PIVER MS ELTABBAKH GH HEMPLING RE RECIO FO BLUMENSON LE
Citation: Ms. Piver et al., PROSPECTIVE SEQUENTIAL TRIALS OF INDUCTION WEEKLY CISPLATIN FOLLOWED BY MONTHLY CISPLATIN, DOXORUBICIN, CYCLOPHOSPHAMIDE AND PACLITAXEL ANDCISPLATIN IN OPTIMAL (LESS-THAN-OR-EQUAL-TO-1 CM) STAGE-III AND STAGE-IV OVARIAN-CANCER, European journal of gynaecological oncology, 19(1), 1998, pp. 5-10
LAPAROSCOPIC-ASSISTED APPLICATION OF INTERSTITIAL BRACHYTHERAPY FOR LOCALLY ADVANCED CERVICAL-CARCINOMA - RESULTS OF A PILOT-STUDY
Authors: RECIO FO PIVER MS HEMPLING RE ELTABBAKH GH HAHN S
Citation: Fo. Recio et al., LAPAROSCOPIC-ASSISTED APPLICATION OF INTERSTITIAL BRACHYTHERAPY FOR LOCALLY ADVANCED CERVICAL-CARCINOMA - RESULTS OF A PILOT-STUDY, International journal of radiation oncology, biology, physics, 40(2), 1998, pp. 411-414
STAGE-I ADENOCARCINOMA OF THE CERVIX - DOES LESION SIZE AFFECT TREATMENT OPTIONS AND PROGNOSIS
Authors: SILVER DF HEMPLING RE PIVER MS RECIO FO ELTABBAKH GH
Citation: Df. Silver et al., STAGE-I ADENOCARCINOMA OF THE CERVIX - DOES LESION SIZE AFFECT TREATMENT OPTIONS AND PROGNOSIS, American journal of clinical oncology, 21(5), 1998, pp. 431-435
PROGESTERONE-RECEPTOR STATUS IS A SIGNIFICANT PROGNOSTIC VARIABLE OF PROGRESSION-FREE SURVIVAL IN ADVANCED EPITHELIAL OVARIAN-CANCER
Authors: HEMPLING RE PIVER MS ELTABBAKH GH RECIO FO
Citation: Re. Hempling et al., PROGESTERONE-RECEPTOR STATUS IS A SIGNIFICANT PROGNOSTIC VARIABLE OF PROGRESSION-FREE SURVIVAL IN ADVANCED EPITHELIAL OVARIAN-CANCER, American journal of clinical oncology, 21(5), 1998, pp. 447-451
COMPLICATIONS RELATED TO INDWELLING CAVAL CATHETERS ON A GYNECOLOGIC ONCOLOGY SERVICE
Authors: SILVER DF HEMPLING RE RECIO FO PIVER MS ELTABBAKH GH
Citation: Df. Silver et al., COMPLICATIONS RELATED TO INDWELLING CAVAL CATHETERS ON A GYNECOLOGIC ONCOLOGY SERVICE, Gynecologic oncology (Print), 70(3), 1998, pp. 329-333
CORRELATION BETWEEN EXTREME DRUG-RESISTANCE ASSAY AND RESPONSE TO PRIMARY PACLITAXEL AND CISPLATIN IN PATIENTS WITH EPITHELIAL OVARIAN-CANCER
Authors: ELTABBAKH GH PIVER MS HEMPLING RE RECIO FO LELE SB MARCHETTI DL BAKER TR BLUMENSON LE
Citation: Gh. Eltabbakh et al., CORRELATION BETWEEN EXTREME DRUG-RESISTANCE ASSAY AND RESPONSE TO PRIMARY PACLITAXEL AND CISPLATIN IN PATIENTS WITH EPITHELIAL OVARIAN-CANCER, Gynecologic oncology (Print), 70(3), 1998, pp. 392-397
5-YEAR SURVIVAL AFTER 2ND-LINE CISPLATIN-BASED INTRAPERITONEAL CHEMOTHERAPY FOR ADVANCED OVARIAN-CANCER
Authors: RECIO FO PIVER MS HEMPLING RE DRISCOLL DL
Citation: Fo. Recio et al., 5-YEAR SURVIVAL AFTER 2ND-LINE CISPLATIN-BASED INTRAPERITONEAL CHEMOTHERAPY FOR ADVANCED OVARIAN-CANCER, Gynecologic oncology, 68(3), 1998, pp. 267-273
REMARKABLE RESPONSE OF PRIMARY SQUAMOUS-CELL CARCINOMA OF THE OVARY TO PACLITAXEL AND CISPLATIN
Authors: ELTABBAKH GH HEMPLING RE RECIO FO ONEILL CP
Citation: Gh. Eltabbakh et al., REMARKABLE RESPONSE OF PRIMARY SQUAMOUS-CELL CARCINOMA OF THE OVARY TO PACLITAXEL AND CISPLATIN, Obstetrics and gynecology, 91(5), 1998, pp. 844-846
IMPORTANCE OF LYMPH-NODE METASTASES IN PRIMARY PERITONEAL CARCINOMA
Authors: ELTABBAKH GH PIVER MS HEMPLING RE WERNESS BA BLUMENSON LE
Citation: Gh. Eltabbakh et al., IMPORTANCE OF LYMPH-NODE METASTASES IN PRIMARY PERITONEAL CARCINOMA, Journal of surgical oncology, 68(3), 1998, pp. 144-148
2ND-LOOK LAPAROTOMY IN ADVANCED OVARIAN-CANCER - A CRITICAL-ASSESSMENT OF MORBIDITY AND IMPACT ON SURVIVAL
Authors: HEMPLING RE WESOLOWSKI JA PIVER MS
Citation: Re. Hempling et al., 2ND-LOOK LAPAROTOMY IN ADVANCED OVARIAN-CANCER - A CRITICAL-ASSESSMENT OF MORBIDITY AND IMPACT ON SURVIVAL, Annals of surgical oncology, 4(4), 1997, pp. 349-354
EXCELLENT LONG-TERM SURVIVAL AND ABSENCE OF VAGINAL RECURRENCES IN 332 PATIENTS WITH LOW-RISK STAGE-I ENDOMETRIAL ADENOCARCINOMA TREATED WITH HYSTERECTOMY AND VAGINAL BRACHYTHERAPY WITHOUT FORMAL STAGING LYMPH-NODE SAMPLING - REPORT OF A PROSPECTIVE TRIAL
Authors: ELTABBAKH GH PIVER MS HEMPLING RE SHIN KH
Citation: Gh. Eltabbakh et al., EXCELLENT LONG-TERM SURVIVAL AND ABSENCE OF VAGINAL RECURRENCES IN 332 PATIENTS WITH LOW-RISK STAGE-I ENDOMETRIAL ADENOCARCINOMA TREATED WITH HYSTERECTOMY AND VAGINAL BRACHYTHERAPY WITHOUT FORMAL STAGING LYMPH-NODE SAMPLING - REPORT OF A PROSPECTIVE TRIAL, International journal of radiation oncology, biology, physics, 38(2), 1997, pp. 373-380
THE ADDITION OF BLEOMYCIN AND DOSE-ESCALATED IFOSFAMIDE TO THE COMBINATION OF CISPLATIN PLUS IFOSFAMIDE DOES NOT IMPROVE SURVIVAL IN ADVANCED OR RECURRENT CERVICAL-CARCINOMA
Authors: HEMPLING RE ELTABBAKH GH PIVER MS RECIO FO ONEILL CP
Citation: Re. Hempling et al., THE ADDITION OF BLEOMYCIN AND DOSE-ESCALATED IFOSFAMIDE TO THE COMBINATION OF CISPLATIN PLUS IFOSFAMIDE DOES NOT IMPROVE SURVIVAL IN ADVANCED OR RECURRENT CERVICAL-CARCINOMA, American journal of clinical oncology, 20(3), 1997, pp. 315-318
2 SEQUENTIAL STUDIES FOR PRIMARY PERITONEAL CARCINOMA - INDUCTION WITH WEEKLY CISPLATIN FOLLOWED BY EITHER CISPLATIN-DOXORUBICIN-CYCLOPHOSPHAMIDE OR PACLITAXEL-CISPLATIN
Authors: PIVER MS ELTABBAKH GH HEMPLING RE RECIO FO BLUMENSON LE
Citation: Ms. Piver et al., 2 SEQUENTIAL STUDIES FOR PRIMARY PERITONEAL CARCINOMA - INDUCTION WITH WEEKLY CISPLATIN FOLLOWED BY EITHER CISPLATIN-DOXORUBICIN-CYCLOPHOSPHAMIDE OR PACLITAXEL-CISPLATIN, Gynecologic oncology, 67(2), 1997, pp. 141-146
THE INFERIOR GLUTEAL FLAP IN THE DIFFICULT VULVAR AND PERINEAL RECONSTRUCTION
Authors: LOREE TR HEMPLING RE ELTABBAKH GH RECIO FO PIVER MS
Citation: Tr. Loree et al., THE INFERIOR GLUTEAL FLAP IN THE DIFFICULT VULVAR AND PERINEAL RECONSTRUCTION, Gynecologic oncology, 66(3), 1997, pp. 429-434
ESTROGEN REPLACEMENT THERAPY FOLLOWING OOPHORECTOMY IN WOMEN WITH A FAMILY HISTORY OF OVARIAN-CANCER
Authors: ELTABBAKH GH PIVER MS HEMPLING RE RECIO FO AIDUK C
Citation: Gh. Eltabbakh et al., ESTROGEN REPLACEMENT THERAPY FOLLOWING OOPHORECTOMY IN WOMEN WITH A FAMILY HISTORY OF OVARIAN-CANCER, Gynecologic oncology, 66(1), 1997, pp. 103-107
HORMONE REPLACEMENT THERAPY AS A RISK FACTOR FOR EPITHELIAL OVARIAN-CANCER - RESULTS OF A CASE-CONTROL STUDY - IN REPLY
Authors: HEMPLING RE WONG C PIVER MS NATARAJAN N METTLIN CJ
Citation: Re. Hempling et al., HORMONE REPLACEMENT THERAPY AS A RISK FACTOR FOR EPITHELIAL OVARIAN-CANCER - RESULTS OF A CASE-CONTROL STUDY - IN REPLY, Obstetrics and gynecology, 90(4), 1997, pp. 642-642
HORMONE REPLACEMENT THERAPY AS A RISK FACTOR FOR EPITHELIAL OVARIAN-CANCER - RESULTS OF A CASE-CONTROL STUDY
Authors: HEMPLING RE WONG C PIVER MS NATARAJAN N METTLIN CJ
Citation: Re. Hempling et al., HORMONE REPLACEMENT THERAPY AS A RISK FACTOR FOR EPITHELIAL OVARIAN-CANCER - RESULTS OF A CASE-CONTROL STUDY, Obstetrics and gynecology, 89(6), 1997, pp. 1012-1016
PACLITAXEL AND CISPLATIN COMBINATION CHEMOTHERAPY IN RECURRENT EPITHELIAL OVARIAN-CANCER
Authors: GOLDBERG JM PIVER MS HEMPLING RE RECIO FO
Citation: Jm. Goldberg et al., PACLITAXEL AND CISPLATIN COMBINATION CHEMOTHERAPY IN RECURRENT EPITHELIAL OVARIAN-CANCER, Gynecologic oncology, 63(3), 1996, pp. 312-317
PRETREATMENT TRANSPERITONEAL LAPAROSCOPIC STAGING PELVIC AND PARAAORTIC LYMPHADENECTOMY IN LARGE (GREATER-THAN-OR-EQUAL-TO-5 CM) STAGE IB2 CERVICAL-CARCINOMA - REPORT OF A PILOT-STUDY
Authors: RECIO FO PIVER MS HEMPLING RE
Citation: Fo. Recio et al., PRETREATMENT TRANSPERITONEAL LAPAROSCOPIC STAGING PELVIC AND PARAAORTIC LYMPHADENECTOMY IN LARGE (GREATER-THAN-OR-EQUAL-TO-5 CM) STAGE IB2 CERVICAL-CARCINOMA - REPORT OF A PILOT-STUDY, Gynecologic oncology, 63(3), 1996, pp. 333-336
LACK OF IMPROVED SURVIVAL PLUS INCREASE IN THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH CLEAR-CELL CARCINOMA OF THE OVARY TREATED WITH PLATINUM VERSUS NONPLATINUM-BASED CHEMOTHERAPY
Authors: RECIO F PIVER MS HEMPLING RE DRISCOLL DL
Citation: F. Recio et al., LACK OF IMPROVED SURVIVAL PLUS INCREASE IN THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH CLEAR-CELL CARCINOMA OF THE OVARY TREATED WITH PLATINUM VERSUS NONPLATINUM-BASED CHEMOTHERAPY, Cancer, 78(10), 1996, pp. 2157-2163
SEVERE RADIATION MORBIDITY IN CARCINOMA OF THE CERVIX - IMPACT OF PRETHERAPY SURGICAL STAGING AND PREVIOUS SURGERY
Authors: FINE BA HEMPLING RE PIVER MS BAKER TR MCAULEY M DRISCOLL D
Citation: Ba. Fine et al., SEVERE RADIATION MORBIDITY IN CARCINOMA OF THE CERVIX - IMPACT OF PRETHERAPY SURGICAL STAGING AND PREVIOUS SURGERY, International journal of radiation oncology, biology, physics, 31(4), 1995, pp. 717-723
IMPACT ON PROGRESSION-FREE SURVIVAL OF ADJUVANT CYCLOPHOSPHAMIDE, VINCRISTINE, DOXORUBICIN (ADRIAMYCIN), AND DACARBAZINE (CYVADIC) CHEMOTHERAPY FOR STAGE-I UTERINE SARCOMA - A PROSPECTIVE TRIAL
Authors: HEMPLING RE PIVER MS BAKER TR
Citation: Re. Hempling et al., IMPACT ON PROGRESSION-FREE SURVIVAL OF ADJUVANT CYCLOPHOSPHAMIDE, VINCRISTINE, DOXORUBICIN (ADRIAMYCIN), AND DACARBAZINE (CYVADIC) CHEMOTHERAPY FOR STAGE-I UTERINE SARCOMA - A PROSPECTIVE TRIAL, American journal of clinical oncology, 18(4), 1995, pp. 282-286
COMPARISON OF IFOSFAMIDE VERSUS CYCLOPHOSPHAMIDE IN COMBINATION WITH CISPLATIN AND DOXORUBICIN (ADRIAMYCIN), AS FIRST-LINE THERAPY FOR ADVANCED EPITHELIAL OVARIAN-CANCER - REPORT OF A PILOT-STUDY
Authors: HEMPLING RE PIVER MS BAKER TR STANTON AM DRISCOLL DL
Citation: Re. Hempling et al., COMPARISON OF IFOSFAMIDE VERSUS CYCLOPHOSPHAMIDE IN COMBINATION WITH CISPLATIN AND DOXORUBICIN (ADRIAMYCIN), AS FIRST-LINE THERAPY FOR ADVANCED EPITHELIAL OVARIAN-CANCER - REPORT OF A PILOT-STUDY, Oncology Reports, 1(3), 1994, pp. 631-635
Risultati: 1-25 | 26-33